CVRx (CVRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors: Michael Dale, Kevin Hykes, and Joseph Slattery is proposed for shareholder approval.
Ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is up for vote.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Grant Thornton LLP is nominated for ratification as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CVRx
- Execution improvements and payer wins position the therapy for broader adoption and growth.CVRX
Canaccord Genuity's 46th Annual Growth Conference - Q2 revenue up 16% year-over-year, but full-year outlook lowered amid sales and payer headwinds.CVRX
Q2 2026 - Barostim therapy gains momentum with expanded access, strong evidence, and accelerating U.S. growth.CVRX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Barostim's clinical success and new coverage drive heart failure market expansion and access.CVRX
46th Annual William Blair Growth Stock Conference - Directors were elected, auditor ratified, and no stockholder questions were raised.CVRX
AGM 2026 - Q1 2026 revenue rose 20% with strong U.S. growth, margin gains, and market expansion efforts.CVRX
Q1 2026 - Q4 revenue up 4%, gross margin at 86%, and BENEFIT-HF trial to triple market size.CVRX
Q4 2025 - Refined strategy, reimbursement wins, and expanded market position set the stage for accelerated growth.CVRX
Piper Sandler 36th Annual Healthcare Conference - Q3 revenue up 27% to $13.4M, with Barostim adoption, reimbursement gains, and strong cash reserves.CVRX
Q3 2024